Trial
NCT01348503
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Indiana University
Collaborators
Celgene Corporation
Condition
Hepatocellular Carcinoma
Intervention
Lenalidomide
Why stopped
Treatment was ineffective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-08-31